Terms: = Leukemia AND RPL22, EAP, 6146
32 results:
1. A primary pediatric acute myelomonocytic leukemia with t(3;21)(q26;q22): A case report.
Duan JX; Liu F; Chang L; Che GL; Yang QX; Teng J; Jian H; Liu XJ; Lai SY
Medicine (Baltimore); 2023 Oct; 102(43):e35721. PubMed ID: 37904382
[TBL] [Abstract] [Full Text] [Related]
2. Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study.
Boissel N; Chiaretti S; Papayannidis C; Ribera JM; Bassan R; Sokolov AN; Alam N; Brescianini A; Pezzani I; Kreuzbauer G; Zugmaier G; Foà R; Rambaldi A
Blood Cancer J; 2023 Jan; 13(1):2. PubMed ID: 36599847
[TBL] [Abstract] [Full Text] [Related]
3. Dissecting the Kinetic Mechanism of Human Lysine Methyltransferase 2D and Its Interactions with the WRAD2 Complex.
Edwardes LV; Caswell SJ; Giurrandino M; Zhai X; Gohlke A; Kostomiris DH; Pollard HK; Pflug A; Hamm GR; Jervis KV; Clarkson PN; Syson K
Biochemistry; 2022 Sep; 61(18):1974-1987. PubMed ID: 36070615
[TBL] [Abstract] [Full Text] [Related]
4. Pediatric patients with acute lymphoblastic leukemia treated with blinatumomab in a real-world setting: Results from the NEUF study.
Locatelli F; Maschan A; Boissel N; Strocchio L; Alam N; Pezzani I; Brescianini A; Kreuzbauer G; Baruchel A
Pediatr Blood Cancer; 2022 Apr; 69(4):e29562. PubMed ID: 35044079
[TBL] [Abstract] [Full Text] [Related]
5. Genomic and clinical characterization of early T-cell precursor lymphoblastic lymphoma.
Xu X; Paxton CN; Hayashi RJ; Dunsmore KP; Winter SS; Hunger SP; Winick NJ; Carroll WL; Loh ML; Devidas M; Gross TG; Bollard CM; Perkins SL; Miles RR
Blood Adv; 2021 Jul; 5(14):2890-2900. PubMed ID: 34297047
[TBL] [Abstract] [Full Text] [Related]
6. Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemia.
Roboz GJ; Larson ML; Rubenstein SE; Solomon SR; Schiller GJ; An Q; Chiarella M; Louie AC; Lin TL
Leuk Lymphoma; 2020 May; 61(5):1188-1194. PubMed ID: 32102577
[TBL] [Abstract] [Full Text] [Related]
7. rpl22L1 induction in colorectal cancer is associated with poor prognosis and 5-FU resistance.
Rao S; Peri S; Hoffmann J; Cai KQ; Harris B; Rhodes M; Connolly DC; Testa JR; Wiest DL
PLoS One; 2019; 14(10):e0222392. PubMed ID: 31581233
[TBL] [Abstract] [Full Text] [Related]
8. Ribosomal Protein rpl22 Controls the Dissemination of T-cell Lymphoma.
Rao S; Cai KQ; Stadanlick JE; Greenberg-Kushnir N; Solanki-Patel N; Lee SY; Fahl SP; Testa JR; Wiest DL
Cancer Res; 2016 Jun; 76(11):3387-96. PubMed ID: 27197189
[TBL] [Abstract] [Full Text] [Related]
9. Role of ribosomal protein mutations in tumor development (Review).
Goudarzi KM; Lindström MS
Int J Oncol; 2016 Apr; 48(4):1313-24. PubMed ID: 26892688
[TBL] [Abstract] [Full Text] [Related]
10. Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B.
Rao S; Lee SY; Gutierrez A; Perrigoue J; Thapa RJ; Tu Z; Jeffers JR; Rhodes M; Anderson S; Oravecz T; Hunger SP; Timakhov RA; Zhang R; Balachandran S; Zambetti GP; Testa JR; Look AT; Wiest DL
Blood; 2012 Nov; 120(18):3764-73. PubMed ID: 22976955
[TBL] [Abstract] [Full Text] [Related]
11. MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia.
Monroe SC; Jo SY; Sanders DS; Basrur V; Elenitoba-Johnson KS; Slany RK; Hess JL
Exp Hematol; 2011 Jan; 39(1):77-86.e1-5. PubMed ID: 20854876
[TBL] [Abstract] [Full Text] [Related]
12. Report of an international expanded access program of imatinib in adults with Philadelphia chromosome positive leukemias.
Capdeville R; Krahnke T; Hatfield A; Ford JM; Van Hoomissen I; Gathmann I
Ann Oncol; 2008 Jul; 19(7):1320-1326. PubMed ID: 18344535
[TBL] [Abstract] [Full Text] [Related]
13. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification.
Mueller D; Bach C; Zeisig D; Garcia-Cuellar MP; Monroe S; Sreekumar A; Zhou R; Nesvizhskii A; Chinnaiyan A; Hess JL; Slany RK
Blood; 2007 Dec; 110(13):4445-54. PubMed ID: 17855633
[TBL] [Abstract] [Full Text] [Related]
14. Identification of leukemia-specific fusion gene transcripts with a novel oligonucleotide array.
Chun SM; Kim YL; Choi HB; Oh YT; Kim YJ; Lee S; Kim TG; Yang EG; Park YK; Kim DW; Han BD
Mol Diagn Ther; 2007; 11(1):21-8. PubMed ID: 17286448
[TBL] [Abstract] [Full Text] [Related]
15. [Study of genes involved in chronic myeloid leukemia with t (3; 21) (q26; q22) in blastic crisis].
Liu XP; Zhang MR; Dai Y; Zhang L; Li R; Hao YS; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):310-3. PubMed ID: 16875579
[TBL] [Abstract] [Full Text] [Related]
16. t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy.
Yin CC; Cortes J; Barkoh B; Hayes K; Kantarjian H; Jones D
Cancer; 2006 Apr; 106(8):1730-8. PubMed ID: 16532439
[TBL] [Abstract] [Full Text] [Related]
17. A novel gene, FGA7, is fused to RUNX1/AML1 in a t(4;21)(q28;q22) in a patient with T-cell acute lymphoblastic leukemia.
Mikhail FM; Coignet L; Hatem N; Mourad ZI; Farawela HM; El Kaffash DM; Farahat N; Nucifora G
Genes Chromosomes Cancer; 2004 Feb; 39(2):110-8. PubMed ID: 14695990
[TBL] [Abstract] [Full Text] [Related]
18. A unique AML1 (CBF2A) rearrangement, t(1;21)(p32;q22), observed in a patient with acute myelomonocytic leukemia.
Cherry AM; Bangs CD; Jones P; Hall S; Natkunam Y
Cancer Genet Cytogenet; 2001 Sep; 129(2):155-60. PubMed ID: 11566347
[TBL] [Abstract] [Full Text] [Related]
19. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
Lo Coco F; Pisegna S; Diverio D
Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
[TBL] [Abstract] [Full Text] [Related]
20. Rearrangements of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: in vitro and in vivo studies.
Zent C; Rowley JD; Nucifora G
Leukemia; 1997 Apr; 11 Suppl 3():273-8. PubMed ID: 9209363
[TBL] [Abstract] [Full Text] [Related]
[Next]
